keyword
MENU ▼
Read by QxMD icon Read
search

Bronchiolitis obliterans syndrome

keyword
https://www.readbyqxmd.com/read/29774598/evaluation-of-current-strategies-for-surveillance-and-management-of-donor-specific-antibodies-single-center-study
#1
Daniel Sullivan, Chul Ahn, Ang Gao, Chantale Lacelle, Fernando Torres, Srinivas Bollineni, Amit Banga, Jessica Mullins, Manish Mohanka, Steve Ring, Michael Wait, Matthias Peltz, Pavan Duddupudi, Dhiraj Surapaneni, Vaidehi Kaza
BACKGROUND: Although, presence of donor specific antibodies (DSA) is known to impact lung allograft, limited data exists regarding DSA management. METHODS: We did a retrospective study at our center evaluating DSA management in adult lung transplant recipients undergoing lung transplantation between January 1, 2010 and June 30, 2014. Study follow up was completed through October 2017. All recipients were stratified into two groups based on the presence or absence of DSA...
May 17, 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29771243/breath-volatile-organic-compounds-of-lung-transplant-recipients-with-and-without-chronic-lung-allograft-dysfunction
#2
Lucas Küppers, Olaf Holz, Sven Schuchardt, Jens Gottlieb, Jan Fuge, Mark Greer, Jens Hohlfeld
Chronic lung allograft dysfunction (CLAD) with its clinical correlative of bronchiolitis obliterans syndrome (BOS) remains the major limiting factor for long-term graft survival. Currently there are no established methods for the early diagnosis or prediction of BOS. To assess the feasibility of breath collection as a non-invasive tool and the potential of breath volatile organic compounds (VOC) for the early detection of BOS, we compared the breath VOC composition between transplant patients without and different stages of BOS...
May 17, 2018: Journal of Breath Research
https://www.readbyqxmd.com/read/29751799/the-aging-lung-tissue-telomere-shortening-in-health-and-disease
#3
Stephanie Everaerts, Elise J Lammertyn, Dries S Martens, Laurens J De Sadeleer, Karen Maes, Aernoud A van Batenburg, Roel Goldschmeding, Coline H M van Moorsel, Lieven J Dupont, Wim A Wuyts, Robin Vos, Ghislaine Gayan-Ramirez, Naftali Kaminski, James C Hogg, Wim Janssens, Geert M Verleden, Tim S Nawrot, Stijn E Verleden, John E McDonough, Bart M Vanaudenaerde
BACKGROUND: Telomere shortening has been associated with several lung diseases. However, telomere length is generally measured in peripheral blood leucocytes rather than in lung tissue, where disease occurs. Consequently, telomere dynamics have not been established for the normal human lung nor for diseased lung tissue. We hypothesized an age- and disease-dependent shortening of lung tissue telomeres. METHODS: At time of (re-)transplantation or autopsy, 70 explant lungs were collected: from unused donors (normal, n = 13) and patients with cystic fibrosis (CF, n = 12), chronic obstructive pulmonary disease (COPD, n = 11), chronic hypersensitivity pneumonitis (cHP, n = 9), bronchiolitis obliterans syndrome (BOS) after prior transplantation (n = 11) and restrictive allograft syndrome (RAS) after prior transplantation (n = 14)...
May 11, 2018: Respiratory Research
https://www.readbyqxmd.com/read/29683998/diagnosis-pathophysiology-and-experimental-models-of-chronic-lung-allograft-rejection
#4
Jason M Gauthier, Daniel Ruiz-Pérez, Wenjun Li, Ramsey R Hachem, Varun Puri, Andrew E Gelman, Daniel Kreisel
Chronic rejection is the Achilles' heel of modern lung transplantation, characterized by a slow, progressive decline in allograft function. Clinically, this manifests as obstructive disease, restrictive disease, or a mixture of the 2 depending on the underlying pathology. The 2 major phenotypes of chronic rejection include bronchiolitis obliterans syndrome and restrictive allograft syndrome. The last decade of research has revealed that each of these phenotypes has a unique underlying pathophysiology which may require a distinct treatment regimen for optimal control...
April 21, 2018: Transplantation
https://www.readbyqxmd.com/read/29683731/bronchiolitis-obliterans-murine-model-induced-by-nitric-acid-aerosol-inhalation-an-economical-and-reproducible-model
#5
Jianing Yin, Xiaobo Ma, Fei Huang, Yucong Ma, Yanan Li
PURPOSE: Bronchiolitis obliterans (BO) is a highly debilitative and fatal syndrome associated with a series of severe lower airway disorders. The pathogenesis of BO is complicated and not entirely understood. An appropriate animal model of BO may aid research into its pathogenesis. Here, we establish a mouse model of BO to provide insight into this disease. MATERIALS AND METHODS: 6-8 week old BABL/c mice were exposed to 5% nitric acid (NA) aerosol through a nebulizer for 3 hours, and controls were exposed to distilled water instead...
April 23, 2018: Experimental Lung Research
https://www.readbyqxmd.com/read/29679771/extracorporeal-photopheresis-improves-survival-in-hematopoietic-cell-transplant-patients-with-bronchiolitis-obliterans-syndrome-without-significantly-impacting-measured-pulmonary-functions
#6
Mehrdad Hefazi, Kimberly J Langer, Nandita Khera, Jill Adamski, Vivek Roy, Jeffrey L Winters, Dennis A Gastineau, Eapen K Jacob, Justin D Kreuter, Manish J Gandhi, William J Hogan, Mark R Litzow, Shahrukh K Hashmi, Hemang Yadav, Vivek N Iyer, J P Scott, Mark E Wylam, Rodrigo Cartin-Ceba, Mrinal M Patnaik
We carried out the first matched retrospective cohort study aimed at studying the safety and efficacy of extracorporeal photopheresis (ECP) for bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation (HCT). Medical records of 1325 consecutive adult patients who underwent HCT between 2005 and 2015 were reviewed. Seventy-four patients (median age, 51 years) with a diagnosis of BOS were included in the study. After propensity-score matching for BOS severity, 26 patients who underwent ≥3 months of ECP were matched to 26 non-ECP-treated patients, who were assigned an index date corresponding to the ECP start date for their matched pairs...
April 18, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29650555/noninfectious-lung-complications-after-allogeneic-haematopoietic-stem-cell-transplantation
#7
Anne Bergeron, Sylvie Chevret, Régis Peffault de Latour, Karine Chagnon, Constance de Margerie-Mellon, Frédéric Rivière, Marie Robin, Jean Mani, Gwenael Lorillon, Gérard Socié, Abdellatif Tazi
Epidemiological data on late noninfectious pulmonary complications (LONIPCs) following allogeneic haematopoietic stem cell transplantation (HSCT) are derived exclusively from retrospective studies and conflicting. We aimed to evaluate prospectively their incidence, risk factors and outcomes.All consecutive patients scheduled to receive allogeneic HSCT between 2006 and 2008, at the university-teaching Saint Louis Hospital (Paris, France) were screened for inclusion. Eligible patients were those surviving at day 100...
April 12, 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/29624575/montelukast-for-bronchiolitis-obliterans-syndrome-after-lung-transplantation-a-randomized-controlled-trial
#8
David Ruttens, Stijn E Verleden, Heleen Demeyer, Dirk E Van Raemdonck, Jonas Yserbyt, Lieven J Dupont, Bart M Vanaudenaerde, Robin Vos, Geert M Verleden
Bronchiolitis obliterans syndrome (BOS) remains the major problem which precludes long-term survival after lung transplantation. Previously, an open label pilot study from our group demonstrated a possible beneficial effect of montelukast in progressive BOS patients with low airway neutrophilia (<15%), and already on azithromycin treatment, in whom the further decline in pulmonary function was attenuated. This was, however, a non-randomized and non-placebo controlled trial. The study design is a single center, prospective, interventional, randomized, double blind, placebo-controlled trial, with a two arm parallel group design and an allocation ratio of 1:1...
2018: PloS One
https://www.readbyqxmd.com/read/29590671/primary-graft-dysfunction-pgd-following-lung-transplantation
#9
Rupal J Shah, Joshua M Diamond
Primary graft dysfunction (PGD) is a form of acute lung injury that results from ischemia reperfusion injury (IRI) and is the major cause of early posttransplant morbidity and mortality. Patients who survive PGD have decreased quality of life, an increased risk of chronic lung allograft dysfunction, specifically bronchiolitis obliterans syndrome, and a significantly increased risk of death. In 2017, the International Society for Heart and Lung Transplantation released updated consensus statements on the PGD definition, most up-to-date PGD risk factors, mechanisms of PGD development, and the state-of-the-art for PGD therapeutics...
April 2018: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29579768/chronic-lung-allograft-dysfunction-evolving-concepts-and-therapies
#10
Ariss DerHovanessian, W Dean Wallace, Joseph P Lynch, John A Belperio, S Sam Weigt
Lung transplantation has become an established therapeutic option for a variety of end-stage lung diseases. Technical advances in graft procurement, implantation, perioperative care, immunosuppression, and posttransplant medical management have led to significant improvements in 1-year survival, but outcomes after the first year have improved minimally over the last two decades. The main limitation to better long-term survival after lung transplantation is chronic lung allograft dysfunction (CLAD). CLAD also impairs quality of life and increases the costs of medical care...
April 2018: Seminars in Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29571601/high-circulating-cd4-cd25-hi-foxp3-t-cell-sub-population-early-after-lung-transplantation-is-associated-with-development-of-bronchiolitis-obliterans-syndrome
#11
Maxim Durand, Philippe Lacoste, Richard Danger, Lola Jacquemont, Carole Brosseau, Eugénie Durand, Gaelle Tilly, Jennifer Loy, Aurore Foureau, Pierre-Joseph Royer, Adrien Tissot, Antoine Roux, Martine Reynaud-Gaubert, Romain Kessler, Sacha Mussot, Claire Dromer, Olivier Brugière, Jean François Mornex, Romain Guillemain, Johanna Claustre, Nicolas Degauque, Antoine Magnan, Sophie Brouard
BACKGROUND: Chronic bronchiolitis obliterans syndrome (BOS) remains a major limitation for long-term survival after lung transplantation. The immune mechanisms involved and predictive biomarkers have yet to be identified. The purpose of this study was to determine whether peripheral blood T-lymphocyte profile could predict BOS in lung transplant recipients. METHODS: An in-depth profiling of CD4+ and CD8+ T cells was prospectively performed on blood cells from stable (STA) and BOS patients with a longitudinal follow-up...
March 20, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29557913/extracorporeal-photopheresis-for-bronchiolitis-obliterans-syndrome-after-lung-transplantation
#12
Ramsey Hachem, Paul Corris
BACKGROUND: Lung transplantation is a therapeutic option for select patients with end-stage lung disease. However, successful lung transplantation is hampered by chronic lung allograft dysfunction (CLAD), in particular bronchiolitis obliterans syndrome (BOS). Although there is no approved or standard treatment for BOS, which may have several distinct phenotypes, extracorporeal photopheresis (ECP) has shown promising results in patients who develop BOS refractory to azithromycin treatment...
March 19, 2018: Transplantation
https://www.readbyqxmd.com/read/29529999/prevalence-of-pre-transplant-anti-hla-antibodies-and-their-impact-on-outcomes-in-lung-transplant-recipients
#13
Ji Eun Park, Chi Young Kim, Moo Suk Park, Joo Han Song, Young Sam Kim, Jin Gu Lee, Hyo Chae Paik, Song Yee Kim
BACKGROUND: Previous studies have suggested that antibodies against human leukocyte antigen (HLA) are associated with worse outcomes in lung transplantation. However, little is known about the factors associated with outcomes following lung transplantation in Asia. Accordingly, we investigated the prevalence of anti-HLA antibodies in recipients before transplantation and assessed their impact on outcomes in Korea. METHODS: A single-center retrospective study was conducted...
March 12, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29501285/impact-and-safety-of-open-lung-biopsy-in-patients-with-acute-respiratory-distress-syndrome-ards
#14
G Ortiz, M Garay, D Mendoza, P Cardinal-Fernández
INTRODUCTION: Acute respiratory distress syndrome (ARDS) is an inflammatory lung disorder, and its pathological hallmark is diffuse alveolar damage (DAD). Given that open lung biopsy (OLB) can sometimes result in severe side effects, it is rarely performed in patients with ARDS. AIM: The aims of this study were to describe: (a) the rate of treatment change associated with the histological result; and (b) the incidence of side effects induced by OLB. DESIGN AND PATIENTS: A retrospective, single-center, descriptive observational study was carried out in Hospital Santa Clara (Bogotá, Colombia) from February 2007 to January 2014...
February 28, 2018: Medicina Intensiva
https://www.readbyqxmd.com/read/29491008/circulating-exosomes-with-distinct-properties-during-chronic-lung-allograft-rejection
#15
Muthukumar Gunasekaran, Monal Sharma, Ramsey Hachem, Ross Bremner, Michael A Smith, Thalachallour Mohanakumar
Circulating exosomes containing donor HLA and lung-associated self-antigens (SAg) are thought to play an important role in allograft rejection after human lung transplantation. We characterized exosomes isolated from serum of 10 lung transplant recipients (LTxR) diagnosed with bronchiolitis obliterans syndrome (BOS) and compared them with exosomes isolated from serum of 10 stable LTxR. Lung-associated SAg (K-α-1-tubulin [Kα1T] and collagen V [Col-V]), MHC class II molecules, costimulatory molecules CD40, CD80, and CD86, and transcription factors class II MHC trans -activator, NF-κB, hypoxia-inducible factor 1-α, IL-1R-associated kinase 1, MyD88, and 20S proteasome were detected in exosomes from BOS, but not stable LTxR...
April 15, 2018: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/29472146/machine-learning-algorithms-utilizing-quantitative-ct-features-may-predict-eventual-onset-of-bronchiolitis-obliterans-syndrome-after-lung-transplantation
#16
Eduardo J Mortani Barbosa, Maarten Lanclus, Wim Vos, Cedric Van Holsbeke, William De Backer, Jan De Backer, James Lee
RATIONALE AND OBJECTIVES: Long-term survival after lung transplantation (LTx) is limited by bronchiolitis obliterans syndrome (BOS), defined as a sustained decline in forced expiratory volume in the first second (FEV1 ) not explained by other causes. We assessed whether machine learning (ML) utilizing quantitative computed tomography (qCT) metrics can predict eventual development of BOS. MATERIALS AND METHODS: Paired inspiratory-expiratory CT scans of 71 patients who underwent LTx were analyzed retrospectively (BOS [n = 41] versus non-BOS [n = 30]), using at least two different time points...
February 19, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29417689/efficacy-of-high-dose-steroids-for-bronchiolitis-obliterans-syndrome-post-pediatric-hematopoietic-stem-cell-transplantation
#17
Ehud Even-Or, Hasan Ghandourah, Muhammad Ali, Joerg Krueger, Neil B Sweezey, Tal Schechter
BOS is the pulmonary manifestation of cGvHD post-allogeneic HSCT. Survival and treatment of this often fatal complication have not improved over the last 20 years and there is no clear standard of care. For the past 10 years, BOS was treated in our center with monthly cycles of HDPS. We reviewed the outcomes of patients with post-HSCT BOS who met the diagnostic criteria for BOS as per the NIH consensus and were treated with at least one cycle of methylprednisolone at a dose of 10-30 mg/kg/d×3 d. We collected demographic and clinical data, responses to treatment and results of pulmonary function tests at several time points...
March 2018: Pediatric Transplantation
https://www.readbyqxmd.com/read/29360666/specific-donor-hla-dr-types-correlate-with-altered-susceptibility-to-development-of-chronic-lung-allograft-dysfunction
#18
Lynn D Haynes, Walker Julliard, Joshua Mezrich, Glen Leverson, Keith C Meyer, William J Burlingham
BACKGROUND: The greatest challenge to long-term graft survival is the development of chronic lung allograft dysfunction (CLAD). Th17 responses to collagen type V (colV) predispose lung transplant patients to the severe obstructive form of CLAD, known as bronchiolitis obliterans syndrome (BOS). In a previous study cohort (n=54), pre-transplant colV responses were increased in recipients expressing HLA-DR15, consistent with the high binding avidity of colV(α1) peptides for HLA-DR15, while BOS incidence, which was known to be strongly associated with post-transplant autoimmunity to colV, was higher in patients who themselves lacked HLA-DR15, but whose lung donor expressed it...
January 23, 2018: Transplantation
https://www.readbyqxmd.com/read/29352737/bronchiolitis-obliterans-syndrome-is-associated-with-increased-p-glycoprotein-expression-and-loss-of-glucocorticoid-receptor-from-steroid-resistant-proinflammatory-cd8-t-cells
#19
G Hodge, S Hodge, P T Nguyen, A Yeo, P Sarkar, A Badiei, C L Holmes-Liew, P N Reynolds, M Holmes
Immunosuppressive therapy fails to suppress the production of proinflammatory cytokines, particularly by CD8+ T cells, in stable lung transplant recipients and those undergoing chronic rejection, suggesting that some patients may become relatively resistant to immunosuppressants such as glucocorticoids (GC). We have shown loss of GC receptor (GCR) from the CD8+ cells, and we hypothesized that the drug membrane efflux pump, p-glycoprotein-1 (Pgp), may also be involved in lymphocyte steroid resistance following lung transplant...
May 2018: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/29322685/feasibility-safety-and-tolerance-of-mesenchymal-stem-cell-therapy-for-obstructive-chronic-lung-allograft-dysfunction
#20
Cesar Ariel Keller, Thomas Arthur Gonwa, David Orel Hodge, Derek Joseph Hei, John Michael Centanni, Abba Chedi Zubair
Feasibility, tolerance, and safety of intravenous infusions of allogeneic mesenchymal stem cell (MSC) therapy in lung transplant recipients with bronchiolitis obliterans syndrome (BOS) are not well established. MSCs were manufactured, cryopreserved, transported to our facility, thawed, and infused into nine recipients with moderate BOS (average drop in forced expiratory volume in 1 second was 56.8% ± 3.2% from post-transplant peak) who were refractory to standard therapy and not candidates for retransplant...
February 2018: Stem Cells Translational Medicine
keyword
keyword
22096
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"